The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | ASCO GI 2021: trial updates
Daniel Catenacci, MD, University of Chicago, Chicago, IL, provides an overview of some of the exciting data presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including updated long-term results from the IMBrave150 (NCT03434379) and KEYNOTE-177 (NCT02563002) studies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
